DECRYPTION – Leqembi was finally approved by European authorities, after having been approved in the United States. Across the Atlantic, it competes with a drug from Eli Lilly.
This is a turnaround that delights the associations of patients suffering from Alzheimer's disease. This summer, the European Medicines Agency (EMA) ruled against the placing on the European market of Leqembi, a drug from the Japanese laboratory Eisai and the American company Biogen, raising great hopes among patients.
On November 14, the EMA changed its mind and decided to approve it for a restricted category of patients. In July, she judged the unfavorable relationship between the benefits provided by the drug and its risks (mainly swelling and potential hemorrhage in the brain) in the case of prescription to a large population.
Also read
Alzheimer's disease: two new risk factors identified
She now recommends it for a restricted population: people suffering from Alzheimer's disease at an early stage, and having only one copy, or none, of a gene promoting the side effects of the drug. In the United States, one in 50 people have two copies of this gene, according to…
This article is reserved for subscribers. You have 81% left to discover.
Black Friday
-70% on digital subscription
Already subscribed? Log in
